This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Worley, B. S. Articles by Berzofsky, J. A. Search for Related Content PubMed PubMed Citation Articles by Worley, B. S. Articles by Berzofsky, J. A.

Antigenicity of Fusion Proteins from Sarcoma-associated Chromosomal Translocations¹

Metabolism Branch [B. S. W., L. T. v. d. B., T. J. G., C. D. P., E. M. D., J. A. B.] and Pediatrics Branch [L. J. H.], National Cancer Institute, Bethesda, Maryland 20892; Immunex Corporation, Seattle, Washington 98101-2936 [E. K. T.]; and Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, Maryland 20892 [F. M. M.]

Synovial sarcoma (SS), clear cell sarcoma (CCS), and desmoplastic small round cell tumor (DSRCT) are soft-tissue malignancies occurring primarily in adolescents and young adults. These tumors contain specific chromosomal translocations that fuse the 5' region of one gene with the 3' region of another, resulting in the formation of characteristic fusion proteins. These translocations are unique to tumor cells and may be required for persistence, thereby serving as targets for immunotherapy. It was hypothesized that the fusion breakpoint sequences associated with SS, CCS, and DSRCT can serve as tumor-specific neoantigens. To test this, peptides corresponding to the fusion breakpoints were designed and assessed for ability to bind to various class I HLA molecules. Two peptides derived from the SS breakpoint specifically bind the HLA-B7 antigen, and a 10-amino acid minimal epitope was identified for this interaction. Specific binding of a SS peptide and a CCS peptide to HLA-B27 molecule was also observed. Finally, a peptide designed from the DSRCT breakpoint specifically binds the HLA-A3 molecule, and a 9-amino acid optimal epitope was identified for this interaction. The physiological/immunological relevance of these peptide/MHC interactions was demonstrated by the induction of SS-specific CTLs from normal donor lymphocytes using in vitro stimulation with autologous, peptide-pulsed dendritic cells and by the ability of these CTLs to lyse human SS tumor cells endogenously expressing the full-length fusion protein. These results suggest that sequences in the fusion region of sarcoma-associated chimeras can bind class I HLA molecules and serve as neoantigens. These may be useful for the development of novel immunotherapies for sarcoma patients with appropriate HLA molecules and tumors bearing these translocations.

This article has been cited by other articles:

				R. HUHN, M. S. STAEGE, M. HESSE, B. LIEBIG, and S. E.G. BURDACH Cleavage of the Ewing Tumour-specific EWSR1-FLI1 mRNA by Hammerhead Ribozymes Anticancer Res, June 1, 2009; 29(6): 1901 - 1908. [Abstract] [Full Text] [PDF]

				C. L. Mackall, E. H. Rhee, E. J. Read, H. M. Khuu, S. F. Leitman, D. Bernstein, M. Tesso, L. M. Long, D. Grindler, M. Merino, et al. A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas Clin. Cancer Res., August 1, 2008; 14(15): 4850 - 4858. [Abstract] [Full Text] [PDF]

				M. Sensi and A. Anichini Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy Clin. Cancer Res., September 1, 2006; 12(17): 5023 - 5032. [Abstract] [Full Text] [PDF]

				L. T. van den Broeke, C. D. Pendleton, C. Mackall, L. J. Helman, and J. A. Berzofsky Identification and Epitope Enhancement of a PAX-FKHR Fusion Protein Breakpoint Epitope in Alveolar Rhabdomyosarcoma Cells Created by a Tumorigenic Chromosomal Translocation Inducing CTL Capable of Lysing Human Tumors Cancer Res., February 1, 2006; 66(3): 1818 - 1823. [Abstract] [Full Text] [PDF]

				T. Tsukahara, Y. Nabeta, S. Kawaguchi, H. Ikeda, Y. Sato, K. Shimozawa, K. Ida, H. Asanuma, Y. Hirohashi, T. Torigoe, et al. Identification of Human Autologous Cytotoxic T-Lymphocyte-Defined Osteosarcoma Gene That Encodes a Transcriptional Regulator, Papillomavirus Binding Factor Cancer Res., August 1, 2004; 64(15): 5442 - 5448. [Abstract] [Full Text] [PDF]

				K. Ida, S. Kawaguchi, Y. Sato, T. Tsukahara, Y. Nabeta, H. Sahara, H. Ikeda, T. Torigoe, S. Ichimiya, K. Kamiguchi, et al. Crisscross CTL Induction by SYT-SSX Junction Peptide and Its HLA-A*2402 Anchor Substitute J. Immunol., July 15, 2004; 173(2): 1436 - 1443. [Abstract] [Full Text] [PDF]

				Y. Toyoshima, M. Karas, S. Yakar, J. Dupont, Lee Helman, and D. LeRoith TDAG51 Mediates the Effects of Insulin-like Growth Factor I (IGF-I) on Cell Survival J. Biol. Chem., June 11, 2004; 279(24): 25898 - 25904. [Abstract] [Full Text] [PDF]

				L. T. van den Broeke, E. Daschbach, E. K. Thomas, G. Andringa, and J. A. Berzofsky Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity J. Immunol., December 1, 2003; 171(11): 5842 - 5852. [Abstract] [Full Text] [PDF]

				C.-C. Chang and V. B. Shidham Molecular Genetics of Pediatric Soft Tissue Tumors: Clinical Application J. Mol. Diagn., August 1, 2003; 5(3): 143 - 154. [Abstract] [Full Text] [PDF]

				S A Burchill Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities J. Clin. Pathol., February 1, 2003; 56(2): 96 - 102. [Abstract] [Full Text] [PDF]

				Y. Sato, Y. Nabeta, T. Tsukahara, Y. Hirohashi, R. Syunsui, A. Maeda, H. Sahara, H. Ikeda, T. Torigoe, S. Ichimiya, et al. Detection and Induction of CTLs Specific for SYT-SSX-Derived Peptides in HLA-A24+ Patients with Synovial Sarcoma J. Immunol., August 1, 2002; 169(3): 1611 - 1618. [Abstract] [Full Text] [PDF]

				T. J. Cummings, N. M. Brown, and T. T. Stenzel TaqMan Junction Probes and the Reverse Transcriptase Polymerase Chain Reaction: Detection of Alveolar Rhabdomyosarcoma, Synovial Sarcoma, and Desmoplastic Small Round Cell Tumor Ann. Clin. Lab. Sci., July 1, 2002; 32(3): 219 - 224. [Abstract] [Full Text] [PDF]

				Y. Hirohashi, T. Torigoe, A. Maeda, Y. Nabeta, K. Kamiguchi, T. Sato, J. Yoda, H. Ikeda, K. Hirata, N. Yamanaka, et al. An HLA-A24-restricted Cytotoxic T Lymphocyte Epitope of a Tumor-associated Protein, Survivin Clin. Cancer Res., June 1, 2002; 8(6): 1731 - 1739. [Abstract] [Full Text] [PDF]